P. Ju
2014
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Clinical Focus
Abstract
Objective To investigate the clinical value of levocarnitine in the treatment of heart failure in ischemic cardiomyopathy.Methods The study selected 127 patients with heart failure in ischemic cardiomyopathy from the hospital,who were randomly divided into two groups:control group and observation group.The control group included 63 patients who received routine treatment,while the observation group included 64 patients who received routine treatment and levocarnitine treatment.Course of treatment was 3months.Improvement situation of clinical symptoms,changes of clinical indicators,clinical efficacy and adverse reactions were compared between two groups.Results After treatment,left ventricular ejection fraction,left ventricular shortening fraction,cardiac output,stroke volume and 6min walking distance increased significantly in two groups.Left ventricular end diastolic diameter,left ventricular end systolic diameter and plasma B type natriuretic peptide decreased significantly in two groups.Left ventricular ejection fraction,left ventricular shortening fraction,cardiac output,stroke volume and 6 min walking distance in observation group were significantly larger than those of control group.Left ventricular end diastolic diameter,left ventricular end systolic diameter and plasma B type natriuretic peptide in observation group were significantly less than those of control group.The disappearance rate of chest diseases symptom,shortness of breath symptom,fatigue symptom and swelling symptom,and total effective rate of therapy in observation group were significantly higher than those of control group(all P 0.05).Conclusion Levocarnitine could obviously improve clinical symptoms of patients with heart failure in ischemic cardiomyopathy,which could also significantly improve clinical indexes.Clinical efficacy of levocarnitine on ischemic cardiomyopathy is significant.It has less adverse reaction and more safety.